moderna is pioneering messenger rna therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. this breakthrough platform addresses currently undruggable targets, and offers a superior alternative to existing drug modalities for a wide range of disease conditions. moderna has developed a broad intellectual property estate including more than 200 patent applications with more than 10,000 claims ranging from novel nucleotide chemistries to specific drug compositions. the company plans to develop and commercialize its innovative mrna drugs—initially for rare diseases and oncology—while partnering drug candidates in other therapeutics areas in order to rapidly deliver this innovation to patients. based in cambridge, massachusetts, moderna is privately held and was founded in 2010 by flagship venturelabs in association with leading scientists from boston children’s hospital a
Company profile
Ticker
MRNA, MRNA-MM
Exchange
Website
CEO
Stephane Bancel
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Moderna Therapeutics, Inc.
SEC CIK
Corporate docs
Subsidiaries
Moderna Australia Pty Ltd • Moderna Biopharma Canada Corporation • Moderna Biotech Distributor UK Ltd. • Moderna Biotech Kenya Manufacturing Ltd. • Moderna Biotech Manufacturing UK Ltd. • Moderna Biotech Securities, Inc. • Moderna Biotech Singapore Pte. Ltd. • Moderna Biotech UK Limited • Moderna Charitable Foundation, Inc. • Moderna Denmark ApS ...
IRS number
813467528
MRNA stock data
Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
2 May 24
8-K
Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates
2 May 24
DEFA14A
Additional proxy soliciting materials
21 Mar 24
DEF 14A
Definitive proxy
21 Mar 24
ARS
2023 FY
Annual report to shareholders
15 Mar 24
PRE 14A
Preliminary proxy
11 Mar 24
S-8
Registration of securities for employees
23 Feb 24
10-K
2023 FY
Annual report
23 Feb 24
8-K
Moderna Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Updates
22 Feb 24
8-K
Moderna Provides Business and Pipeline Updates at 42nd Annual J.P. Morgan Healthcare Conference
8 Jan 24
Transcripts
MRNA
Earnings call transcript
2024 Q1
2 May 24
MRNA
Earnings call transcript
2023 Q4
22 Feb 24
MRNA
Earnings call transcript
2023 Q3
2 Nov 23
MRNA
Earnings call transcript
2023 Q2
3 Aug 23
MRNA
Earnings call transcript
2023 Q2
3 Aug 23
MRNA
Earnings call transcript
2023 Q1
4 May 23
MRNA
Earnings call transcript
2022 Q4
23 Feb 23
MRNA
Earnings call transcript
2022 Q3
3 Nov 22
MRNA
Earnings call transcript
2022 Q2
3 Aug 22
MRNA
Earnings call transcript
2022 Q1
4 May 22
Latest ownership filings
144
Notice of proposed sale of securities
22 May 24
4
NOUBAR AFEYAN
17 May 24
4
Stephen Hoge
17 May 24
144
Notice of proposed sale of securities
15 May 24
144
Notice of proposed sale of securities
15 May 24
4
Stephen Hoge
13 May 24
4
NOUBAR AFEYAN
10 May 24
144
Notice of proposed sale of securities
10 May 24
144
Notice of proposed sale of securities
8 May 24
4
Stephen Berenson
7 May 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 2.07 bn | 2.07 bn | 2.07 bn | 2.07 bn | 2.07 bn | 2.07 bn |
Cash burn (monthly) | 285.67 mm | 115.83 mm | 422.00 mm | 422.92 mm | 329.67 mm | 240.17 mm |
Cash used (since last report) | 504.61 mm | 204.61 mm | 745.43 mm | 747.05 mm | 582.33 mm | 424.23 mm |
Cash remaining | 1.57 bn | 1.87 bn | 1.33 bn | 1.32 bn | 1.49 bn | 1.65 bn |
Runway (months of cash) | 5.5 | 16.1 | 3.1 | 3.1 | 4.5 | 6.9 |
Institutional ownership, Q1 2024
25.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 439 |
Opened positions | 81 |
Closed positions | 336 |
Increased positions | 142 |
Reduced positions | 121 |
13F shares | Current |
---|---|
Total value | 7.19 tn |
Total shares | 97.06 mm |
Total puts | 2.08 mm |
Total calls | 2.77 mm |
Total put/call ratio | 0.8 |
Largest owners | Shares | Value |
---|---|---|
Baillie Gifford & Co | 44.66 mm | $4.76 tn |
Flagship Ventures Fund IV General Partner | 17.58 mm | $0.00 |
Bancel Stephane | 9.05 mm | $0.00 |
Banque Pictet & Cie | 3.16 mm | $336.91 bn |
BK Bank Of New York Mellon | 2.31 mm | $245.72 bn |
Mawer Investment Management | 1.92 mm | $204.23 bn |
CMTDF Sumitomo Mitsui Trust | 1.55 mm | $164.72 bn |
ARK Investment Management | 1.22 mm | $129.72 bn |
California Public Employees Retirement System | 1.13 mm | $120.41 bn |
Swiss National Bank | 970.60 k | $103.43 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 May 24 | Stephen Hoge | Common Stock | Sell | Dispose S | No | Yes | 127.49 | 15,000 | 1.91 mm | 1,471,508 |
15 May 24 | Afeyan Noubar | Common Stock | Sell | Dispose S | No | Yes | 129.15 | 200 | 25.83 k | 1,996,931 |
15 May 24 | Afeyan Noubar | Common Stock | Sell | Dispose S | No | Yes | 128.7466 | 5,711 | 735.27 k | 1,997,131 |
15 May 24 | Afeyan Noubar | Common Stock | Sell | Dispose S | No | Yes | 127.7063 | 2,600 | 332.04 k | 2,002,842 |
15 May 24 | Afeyan Noubar | Common Stock | Sell | Dispose S | No | Yes | 126.6208 | 2,001 | 253.37 k | 2,005,442 |
15 May 24 | Afeyan Noubar | Common Stock | Sell | Dispose S | No | Yes | 125.5251 | 4,488 | 563.36 k | 2,007,443 |
10 May 24 | Stephen Hoge | Common Stock | Sell | Dispose S | No | No | 120.9573 | 255 | 30.84 k | 1,486,508 |
9 May 24 | Stephen Hoge | Common Stock | Option exercise | Acquire M | No | No | 0 | 522 | 0.00 | 1,486,763 |
9 May 24 | Stephen Hoge | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 522 | 0.00 | 1,568 |
8 May 24 | Afeyan Noubar | Common Stock | Sell | Dispose S | No | Yes | 122.0689 | 7,996 | 976.06 k | 2,011,931 |
News
8 Health Care Stocks Whale Activity In Today's Session
23 May 24
Moderna Options Trading: A Deep Dive into Market Sentiment
23 May 24
Experts Predict Rise In COVID-19 Cases: Vaccine Stocks Climb
22 May 24
Why XP Shares Are Trading Lower By Around 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
22 May 24
'Disease Experts Predict A Small Rise In Covid-19 Cases This Summer' - CNBC
22 May 24
Press releases
Moderna Announces Data to be Presented at 2024 ASCO Annual Meeting
22 May 24
Moderna to Present at Upcoming Conferences in May/June 2024
13 May 24
Moderna Announces Update on Investigational RSV Vaccine
10 May 24
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024
8 May 24
Flagship Pioneering Unveils Prologue Medicines to Unlock the Therapeutic Potential of the Viral Proteome
7 May 24